Global Mycoplasma Testing Market Size study & Forecast, by Product (Instruments, Kits and Reagents), by Technology (PCR, ELISA, Enzymatic Methods, DNA Staining, Other Technologies), by Application (Cell Line Testing, Bioproduction Testing, Other Applicati

Global Mycoplasma Testing Market Size study & Forecast, by Product (Instruments, Kits and Reagents), by Technology (PCR, ELISA, Enzymatic Methods, DNA Staining, Other Technologies), by Application (Cell Line Testing, Bioproduction Testing, Other Applications) and Regional Analysis, 2023-2030

Global Mycoplasma Testing Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030 Mycoplasma testing is a process of detecting and confirming the presence of mycoplasma contamination in biological products, cell cultures, and other materials used in biopharmaceutical and biomedical research. Mycoplasmas are a type of bacteria that lack a cell wall, making them resistant to many antibiotics and challenging to eliminate from cell cultures. The Mycoplasma Testing Market is expanding because of factors such as rising biopharmaceutical and biotechnology research, increasing cell culture applications, and increasing investment in pharmaceutical research and development activities.

Pharmaceutical companies invest substantial amounts of money in research and development to discover, develop new drugs and therapies. Mycoplasma contamination in cell cultures can jeopardize these investments by compromising the integrity of experimental results and the safety of the developed products. Mycoplasma testing becomes a crucial component of quality control to protect the substantial financial investments made in pharmaceutical R&D. According to Statista, global spending on pharmaceutical research and development in the year 2020 stood at USD 211 billion which increased to USD 244 billion in the year 2922 and it is projected to reach at USD 302 billion by year 2028. Thus, rising investment in pharmaceutical research and development activities is driving the market growth. In addition, increased government initiatives and funding for research activities and technological advancements in testing methods are creating new opportunities for market growth. However, the high cost of mycoplasma testing and the availability of other alternative testing technologies stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Mycoplasma Testing Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the rising healthcare expenditure, increased incidence of respiratory disorders, rising drug discovery activities and increased investment in R&D activities in the region. Asia Pacific is expected to grow at the fastest rate over the forecast period, owing to factors such as rising government investment in the pharmaceutical industry, and rising drug discovery activities in the region.

Major market player included in this report are:
Thermo Fisher Scientific, Inc.
Merck KGaA
Lonza Group AG
Charles River Laboratories International, Inc.
PromoCell GmbH
American Type Culture Collection
Asahi Kasei Medical Co., Ltd.
Sartorius AG
InvivoGen
Eurofins Scientific

Recent Developments in the Market:
 In April 2023, Agathos Biologics introduced a suite of analytical testing services catering to life science researchers. The company exclusively employs QIAcuity instrumentation and utilizes assays developed by QIAGEN. Additionally, Agathos has entered a collaborative partnership with QIAGEN to undertake testing and validation processes for mycoplasma and recombinant adeno-associated viral vector (rAAV) assay.
 In April 2022, Performer Availability Screening Service, Inc. (PASS) has collaborated with Spankchain to launch a program focused on screening and treating Mycoplasma genitalium infection within the Las Vegas performer community. The primary goal of this initiative is to offer complimentary services to a maximum of 1000 performers.

Global Mycoplasma Testing Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Product, Technology, Application, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:
Instruments
Kits and Reagents

By Technology:
PCR
ELISA
Enzymatic Methods
DNA Staining
Other Technologies

By Application:
Cell Line Testing
Bioproduction Testing
Other Applications

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Thermo Fisher Scientific, Inc.
Merck KGaA
Lonza Group AG
Charles River Laboratories International, Inc.
PromoCell GmbH
American Type Culture Collection
Asahi Kasei Medical Co., Ltd.
Sartorius AG
InvivoGen
Eurofins Scientific

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.